Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature

Azzazi, Yousra; Abdelkader, Heba A.; Khedr, Hadeer; El-Komy, Mohamed H.M.

doi:10.1111/cup.14235

Cited by 6 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxford-AstraZeneca adenoviral vaccine (ChAdOx1 nCoV-19 AZD1222) ( 69 – 79 ). Johnson & Johnson adenoviral vaccine (Ad26.COV2.S) ( 80 – 82 ), and inactivated vaccines [Sinovac CoronaVac ( 83 ), Bharat Biotech Covaxin ( 84 ), Sinopharm BBiBP-CorV] ( 85 , 86 ) ( Supplementary Table 2 ).…”

Section: Anti-sars-cov-2 Vaccination-induced Cutaneous Vasculitismentioning

confidence: 99%

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

Cutaneous vasculitides encompass a heterogeneous group of clinicopathological entities, which may occur as single-organ vasculitis of the skin or present as skin-limited variant of systemic vasculitis (i.e., skin-limited ANCA-associated vasculitis), and are triggered by various factors, including infections, drugs and vaccines. The COVID-19 pandemic has challenged us with a variety of both disease- and vaccine-associated skin manifestations, including vasculitis. Among the latter, cutaneous small-vessel vasculitis, previously known as leukocytoclastic vasculitis, seems to be the most reported in either scenario, i.e., natural infection and vaccination. Vasculopathy without true vasculitic changes on histology develops in but a minority of cases, mostly severe/critical COVID-19 patients, and appears to be the result of endothelial injury due to pauci-immune thromboembolic mechanisms. Herein, we provide an overview of the available literature on COVID-19-associated and anti-SARS-CoV-2-vaccine-associated cutaneous vasculitis. Although evidence is mostly limited to isolated reports, with a proportion of cases lacking histopathological confirmation, ample overlap with pre-pandemic forms is shown.

show abstract

Section: Anti-sars-cov-2 Vaccination-induced Cutaneous Vasculitismentioning

confidence: 99%

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The link between vasculitis and vaccination from a pathogenetic point of view is not clear but may involve an immune complex and antibodies deposition in the blood vessel walls (39). Recently, cytoplasmatic granular positivity for SARS-CoV-2 Spike protein was found in some skin specimens of infection-related CV (40).…”

Section: Case Nomentioning

confidence: 99%

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

et al. 2022

View full text Add to dashboard Cite

Cutaneous vasculitis (CV) is an inflammatory skin-limited vascular disease affecting the dermal and/or hypodermal vessel wall. From the pathogenetic point of view, idiopathic forms are described as well as the induction from various triggers, such as drugs, infections, and vaccines. Following SARS-CoV-2 pandemic outbreak, cases of CV induced by both COVID-19 and COVID-19 vaccinations have been reported in literature. The aim of our work was to collect multiple cases available in the literature and analyze the frequency of the different forms of induced vasculitis, as well as their histological and immunopathological features. Although rare, CV induced by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and vaccines may provide interesting insights into the pathogenesis of these inflammatory processes that may in the future be useful to understand the mechanisms underlying cutaneous and systemic vasculitis.

show abstract